How your body makes cannabinoids

Your body produces its own cannabis-like molecules that regulate pain, mood, sleep, appetite, and immune function — and everyday habits like exercise, diet, and stress management directly shape how well this system works

Your body has a built-in system for producing molecules that work almost identically to the cannabinoids found in cannabis — and it has been running this system for at least 600 million years of evolution [1]. The endocannabinoid system (ECS) is a vast signaling network that helps regulate pain, inflammation, mood, sleep, appetite, memory, and immune function. Two molecules sit at its center: anandamide (nicknamed the "bliss molecule" after the Sanskrit word for joy) and 2-arachidonoylglycerol (2-AG). Both are made on demand inside your cells and act on cannabinoid receptors throughout your brain, nervous system, and body [1]. Understanding the ECS helps explain why exercise reliably lifts mood, why chronic stress disrupts sleep and appetite, and why an omega-3-rich diet has such wide-ranging effects on wellbeing.

The ECS: receptors, molecules, and enzymes

The endocannabinoid system has three core components: the receptors it signals through, the endocannabinoids that activate them, and the enzymes that make and break them down [1].

CB1 and CB2 receptors are the two main cannabinoid receptors in the body. CB1 receptors are found predominantly in the brain and central nervous system — particularly in regions controlling movement (basal ganglia, cerebellum), memory and learning (hippocampus), reward and mood (prefrontal cortex, limbic system), and pain processing (dorsal horn of the spinal cord). CB2 receptors are concentrated in immune cells, the spleen, and peripheral tissues, where they govern inflammation and immune modulation [1][2]. When cannabinoid receptors are activated, they typically act as brakes on their target cells — reducing neuronal firing, dampening inflammatory signaling, and modulating the release of other neurotransmitters including glutamate, GABA, dopamine, and serotonin.

Anandamide (AEA) is produced from a phospholipid precursor in the cell membrane and released in response to neuronal activity. It is sometimes called a partial agonist — it activates both CB1 and CB2 receptors but with lower efficacy than THC, producing more subtle, tightly regulated effects. Anandamide also activates TRPV1 channels (the same receptor activated by capsaicin), adding pain-modulating effects beyond the CB receptors themselves. It is rapidly broken down by the enzyme FAAH (fatty acid amide hydrolase), which is why its effects are brief and localized [1].

2-AG is produced in higher concentrations than anandamide and acts as a full agonist at both CB1 and CB2 receptors. It is the primary endocannabinoid involved in retrograde signaling — a process where postsynaptic neurons send chemical signals backward across the synapse to dampen the activity of the presynaptic neuron. This retrograde inhibition is how the ECS modulates the release of other neurotransmitters, providing "on demand" regulation of excitatory and inhibitory signaling throughout the nervous system. 2-AG is broken down by the enzyme MAGL (monoacylglycerol lipase) [1].

Pain and inflammation: the ECS as a natural analgesic

The ECS plays a central role in pain perception at every level of the nervous system — in the peripheral tissues where pain signals originate, in the spinal cord where they are processed, and in the brain where they are experienced [2]. CB1 receptors in the dorsal horn of the spinal cord dampen the transmission of pain signals ascending toward the brain; CB2 receptors in peripheral tissue reduce local inflammation that drives sensitization of pain fibers.

When tissue is injured, the ECS is rapidly upregulated — anandamide and 2-AG levels rise at the site of injury, and CB2 receptor expression increases in immune cells recruited to the area [2]. This is not a side effect but a core part of the healing process: the ECS restrains excessive inflammation, limits sensitization of pain neurons, and helps resolve the inflammatory response once it has done its job. Disruption of this system — through chronic stress, nutrient deficiencies, or genetic variants in FAAH — is associated with heightened pain sensitivity and longer recovery from injury.

This is why omega-3 fatty acids, which are structural precursors to endocannabinoids, matter for pain management [5]. EPA and DHA from fish oil are converted into a class of omega-3-derived endocannabinoids — including DHEA-EA (docosahexaenoyl ethanolamide, also called synaptamide) — that activate cannabinoid and related receptors with anti-inflammatory effects. People who consume diets high in processed seed oils (rich in omega-6 arachidonic acid) and low in omega-3s may shift endocannabinoid production toward more pro-inflammatory substrates. See our omega-3 pages and seed oils page for more.

Mood, anxiety, and stress regulation

The ECS is intimately connected to the brain's stress response system [3]. In the prefrontal cortex, hippocampus, and amygdala — regions central to emotional processing — CB1 receptors regulate the hypothalamic-pituitary-adrenal (HPA) axis that governs cortisol release. When a stressor is acute, the ECS provides a "stress buffer," dampening the cortisol response and facilitating recovery. In chronic stress, endocannabinoid signaling is depleted — anandamide levels fall, CB1 receptor density decreases, and the stress system loses its natural brake [3].

Clinical research shows that people with anxiety disorders and PTSD have measurable deficits in endocannabinoid tone — lower circulating anandamide and altered CB1 receptor binding in stress-related brain regions. Animal models of depression consistently show upregulation of FAAH (faster anandamide breakdown), reduced CB1 receptor function, and impaired neurogenesis in the hippocampus — all of which reverse when endocannabinoid signaling is restored pharmacologically or through lifestyle interventions [3].

The connection to the serotonin system is also direct: anandamide inhibits serotonin reuptake and modulates serotonin receptor sensitivity, providing another mechanism through which the ECS influences mood. This overlap explains why many interventions that support the ECS — exercise, omega-3 supplementation, reduced chronic stress — also support serotonin signaling and mood. See our 5-HTP page for more on serotonin precursor support.

Sleep: the ECS keeps your cycles stable

The ECS regulates the architecture of sleep across the night [4]. CB1 receptors are active in brain regions controlling wake-sleep transitions, including the basal forebrain, thalamus, and brainstem nuclei. Anandamide and 2-AG levels follow a circadian pattern — rising during periods of wakefulness (particularly after prolonged wakefulness) and falling after sleep, creating a homeostatic sleep pressure signal that complements the circadian clock system.

Research in animal models shows that ECS signaling specifically stabilizes non-REM sleep — reducing fragmentation (waking up between sleep cycles) and consolidating slow-wave sleep [4]. FAAH inhibition, which raises anandamide levels, extends slow-wave sleep duration and reduces sleep latency (time to fall asleep). Disruptions in ECS signaling fragment sleep architecture even when total sleep time is maintained, which may partly explain why chronic stress — which depletes endocannabinoid tone — is so consistently associated with poor sleep quality even in people who spend adequate time in bed.

How lifestyle shapes your endocannabinoid tone

Exercise is one of the most potent natural upregulators of the ECS. The "runner's high" — the euphoric, analgesic, and anxiolytic effect of sustained aerobic exercise — is mediated substantially by endocannabinoids, not endorphins as was long believed. Serum anandamide rises significantly after moderate-intensity aerobic exercise (running, cycling, swimming) and correlates with reduced anxiety and pain perception. CB1 receptors in mood-related brain areas are required for exercise-induced anxiolysis in animal models.

Omega-3 fatty acids are structural building blocks for endocannabinoid synthesis [5]. EPA and DHA from fatty fish, krill oil, and fish oil supplements are converted into a class of omega-3-derived endocannabinoid-like molecules with anti-inflammatory and neuroprotective effects. Diets chronically low in omega-3s reduce the bioavailability of these precursors and may compromise ECS function.

Chronic stress depletes the ECS by chronically elevating cortisol, which suppresses anandamide production and downregulates CB1 receptors. This creates a self-perpetuating cycle: low endocannabinoid tone reduces stress resilience, making the same stressor feel more severe. Practices that reduce HPA axis reactivity — meditation, breathwork, adequate sleep, cold exposure — also support ECS recovery over time. See our meditation page and cold exposure page for more.

Sleep deprivation reduces CB1 receptor availability and lowers circulating endocannabinoid levels, impairs pain thresholds, and increases appetite — all consistent with ECS suppression. Prioritizing sleep quality is therefore also an ECS-supportive practice.

A diverse, whole-food diet provides fatty acid precursors, polyphenols (some of which modulate FAAH and CB2 receptor activity), and anti-inflammatory compounds that support baseline endocannabinoid tone.

Evidence review

ECS overview: receptors, ligands, and medical potential (Mouslech & Valla, 2009)

This foundational review published in Neuro Endocrinology Letters provided a comprehensive overview of the ECS, including the discovery timeline, receptor distribution throughout the body, the two primary endocannabinoids (anandamide and 2-AG), and their biosynthesis and degradation pathways [1]. The authors described how CB1 receptors dominate in the central nervous system — particularly in the basal ganglia, hippocampus, cerebral cortex, cerebellum, and dorsal horn — while CB2 receptors predominate in immune cells and peripheral tissues. They outlined the broad physiological roles regulated by the ECS: nociception (pain), mood, memory, appetite, and immune function. The review noted that the ECS evolved over approximately 600 million years, predating the evolution of the vertebrate nervous system in its current form, explaining its fundamental regulatory role across so many physiological systems. The paper discussed how both exogenous cannabinoids (plant-derived THC, CBD) and endogenous ligands share this receptor system, and reviewed early evidence that pharmacological modulation of the ECS held promise for pain, neurodegeneration, and psychiatric conditions. While a 2009 paper, the foundational receptor biology and endocannabinoid biochemistry it describes remain the accepted framework in the field.

The ECS as a pain regulation system (Guindon & Hohmann, 2009)

This detailed review in CNS and Neurological Disorders Drug Targets mapped the ECS's role in pain at each level of the neuraxis [2]. At the peripheral level, CB1 and CB2 receptors on sensory neurons (including TRPV1-expressing nociceptors) modulate the threshold for pain signal initiation. In inflamed tissue, 2-AG and anandamide levels rise substantially — a natural anti-nociceptive response. The authors reviewed evidence that pharmacological FAAH inhibition (preventing anandamide breakdown) reduced pain behavior in animal models of inflammatory pain, neuropathic pain, and visceral pain. At the spinal level, CB1 receptor activation in the dorsal horn reduces glutamate-mediated excitatory transmission, limiting ascending pain signaling. Supraspinally, endocannabinoid signaling in the periaqueductal gray (PAG) — a key hub for descending pain inhibition — is required for the analgesic effects of stress and exercise. The review noted that unlike opioids, CB receptor activation does not produce respiratory depression, tolerance develops more slowly, and the wide distribution of CB2 receptors in the periphery offers a route to pain relief with fewer central side effects.

ECS and mood and anxiety disorders (Hill & Gorzalka, 2009)

This review in CNS and Neurological Disorders Drug Targets systematically examined evidence for endocannabinoid involvement in depression and anxiety [3]. The authors catalogued animal models showing that genetic deletion of CB1 receptors or pharmacological FAAH upregulation (which depletes anandamide) produces depressive and anxiety-like phenotypes — reduced sucrose preference, social withdrawal, impaired extinction of conditioned fear, and elevated corticosterone — that resemble rodent models of clinical depression and anxiety. These behaviors reversed with restoration of CB1 signaling. In humans, the paper reviewed PET imaging studies showing reduced CB1 receptor availability in depressed patients in emotion-processing regions including the anterior cingulate cortex and amygdala. The authors discussed the connection between HPA axis dysregulation and ECS deficiency: corticotropin-releasing hormone (CRH) drives FAAH upregulation, accelerating anandamide breakdown and reducing stress buffering capacity. They proposed that chronic stress creates a "deficient endocannabinoid signaling" state that perpetuates anxiety and depression, and that restoring endocannabinoid tone — through lifestyle interventions or pharmacological FAAH inhibition — might complement existing psychiatric treatments.

Endocannabinoid signaling and sleep stability (Pava et al., 2016)

This experimental study published in PLoS One characterized how ECS signaling shapes sleep architecture in mice using in vivo electrophysiology and cannabinoid receptor manipulation [4]. The researchers found that endocannabinoid signaling specifically regulates non-REM (NREM) sleep stability — reducing transitions between NREM and wake states and extending consolidated slow-wave sleep episodes. CB1 receptor blockade with a selective antagonist (SR141716A) increased NREM sleep fragmentation significantly, while FAAH inhibition (raising anandamide levels) had the opposite effect: fewer sleep-wake transitions and more stable slow-wave sleep. The study also documented circadian variation in endocannabinoid signaling: 2-AG levels in the hypothalamus peaked during the light (inactive) phase and fell during the dark (active) phase, consistent with a role in regulating homeostatic sleep pressure. The authors proposed that the ECS works in parallel with adenosine (the classic sleep-pressure signal) to consolidate sleep, and that ECS deficiency — as seen in chronic stress — could contribute to the fragmented sleep architecture commonly observed in anxiety and depression. While a rodent study, the receptor pharmacology is directly translatable, and the findings are consistent with clinical observations of sleep disturbance in patients with low endocannabinoid tone.

Omega-3-derived endocannabinoids (Watson et al., 2019)

This review in Prostaglandins, Leukotrienes and Essential Fatty Acids described an emerging class of endocannabinoid-like molecules derived directly from long-chain omega-3 fatty acids — specifically EPA and DHA [5]. These omega-3-derived molecules, including docosahexaenoyl ethanolamide (DHEA-EA, also called synaptamide), eicosapentaenoyl ethanolamide (EPEA-EA), and their metabolites, are structurally analogous to anandamide but are synthesized from omega-3 rather than omega-6 (arachidonic acid) precursors. The review documented that synaptamide activates CB1 receptors, has neuroprotective effects in brain development, and promotes anti-inflammatory resolution pathways distinct from omega-6-derived endocannabinoids. The authors discussed how dietary fatty acid intake directly shifts the substrate pool available for endocannabinoid synthesis: diets high in arachidonic acid (found in processed foods and seed oils) favor production of the conventional omega-6-derived endocannabinoids (anandamide, 2-AG), while diets rich in EPA/DHA from fatty fish or fish oil supplements shift production toward the omega-3-derived forms with different — and largely more anti-inflammatory — receptor profiles. This provides a direct mechanistic link between omega-3 consumption and ECS function, and explains part of why dietary fatty acid quality has such broad effects on inflammation, mood, and pain sensitivity.

References

Endocannabinoid system: An overview of its potential in current medical practiceMouslech Z, Valla V. Neuro Endocrinology Letters, 2009. PubMed 19675519 →
The endocannabinoid system and painGuindon J, Hohmann AG. CNS and Neurological Disorders Drug Targets, 2009. PubMed 19839937 →
The endocannabinoid system and the treatment of mood and anxiety disordersHill MN, Gorzalka BB. CNS and Neurological Disorders Drug Targets, 2009. PubMed 19839936 →
Endocannabinoid Signaling Regulates Sleep StabilityPava MJ, Makriyannis A, Lovinger DM. PLoS One, 2016. PubMed 27031992 →
Emerging class of omega-3 fatty acid endocannabinoids and their derivativesWatson JE, Kim JS, Das A. Prostaglandins, Leukotrienes and Essential Fatty Acids, 2019. PubMed 31085370 →